Partners

FHU ARRIMAGE consortium in the 3 sites

Academic partners

– UMRS N-GERE, Inserm UMRS 1256, Nutrition-Génétique-Exposition aux Risques Environnementaux. Member of the I-site “LUE” from the University of Lorraine (program GEENAGE). Director: Jean-Louis Guéant, deputy Director: David Meyre – Team «Métabolisme des monocarbones et épigénomique dans les origines de développement des maladies métaboliques héréditaires et complexes», Team leader: Jean-Louis Guéant. – Team «Métabolisme, génomique intégrative et bioinformatique», Team leader: Rémi Houlgatte.

– CERBM-GIE (Centre Européen de Recherche en Biologie et en Médecine)-IGBMC, CNRS UMR 7104 – Inserm U 964 – Université de Strasbourg. Directeur: A Beretz.–P2.1. Equipe STRESSMETAINFLAMMATION, signalisation cellulaire du stress dans le métabolisme et l’inflammation. Responsable de l’équipe: Roméo Ricci – P2.2. Equipe Biologie Moléculaire et Cellulaire des Cancers du Sein. Responsable de l’équipe: Catherine Tomasetto

– Inserm UMR_S1113, IRFAC (Interface Recherche Fondamentale et Appliquée en Cancérologie). Inserm / Université de Strasbourg. Directeur : Jean-Noël Freund – Equipe : Emergence des Cellules Souches et Initiation Tumorale (ECSIT). Responsable de l’équipe: Jean-Noël Freund

– UMR MEDyC CNRS/URCA 369 (Matrice Extracellulaire et Dynamique Moléculaire), CNRS/Université Reims-Champagne Ardenne. Directeur: Laurent MARTINY. – Equipe Vieillissement matriciel et remodelage vasculaire. Responsables: Stéphane Jaisson /Laurent Duca

– Labex Medalis (Director: Sylviane Muller), part of the action « Initiatives of Excellence » (IDEX) from the University of Strasbourg, with the UMR7242 CNRS « Biotechnologie et signalisation cellulaire». Directeur UMR: Jean-Luc Galzi – Equipe Neuroimmunologie et thérapie peptidique. Co-responsable de l’équipe: Sylviane Muller ; and UMS3286 CNRS (PCBIS) Directeur : Pascal Villa.

– EA APEMAC « Adaptation, mesure et évaluation en santé. Approches interdisciplinaires ». Directeur F Guillemin. – Equipe MICS (Nancy): « Mesure et interventions complexes en santé ». Elle rassemble des spécialistes en épidémiologie, médecine clinique, sciences du sport, et sociologie. Responsable: N Agrinier – Equipe Epsam (Metz): « Adaptation, comportements de santé et prise en charge psychologique ». Responsable: C Tarquinio

– Associated Units. UMRS Inserm UL 1116 DCAC (Défaillance Cardiovasculaire Aigüe et Chronique, directeur P Lacolley) and UMRS Inserm-UL IADI (Imagerie Adaptative Diagnostique et Interventionnelle, directeur J Felblinger), Pôle AM2I, LORIA, IECL, CRAN and related platforms (SMEC and SCIARAT) (MD Devignes, Anne Gegout-Petit and Amédéo Napoli).

Departments of Regional University Hospital Centers

CHRU Nancy :

Pôle Digestif. – Hépato Gastro-Entérologie (Head, JP Bronowicki, deputy, L Peyrin Biroulet) – Chirurgie Digestive et Générale (L Brunaud, N Reibel) – Diabétologie, Maladies Métaboliques et Nutrition (O Ziegler, D Quilliot). Centre spécialisé de l’obésité (CSO) (Pr O Ziegler) ;Pôle Pédiatrie. National reference centre for rare metabolic diseases (Coordinator: F Feillet). The centre is one of the centres worldwide with leading expertise on inherited disorders of 1-CM; Pôle laboratoires. – Biochimie-Biologie Moléculaire-Nutrition-Métabolisme (head, JL Guéant, RM Guéant-Rodiguez, A Oussalah, D Meyre)

Hôpitaux Universitaires de Strasbourg (HUS)

Service de Médecine Interne, Diabète et Maladies métaboliques, Pôle Medecine-Interne-Rhumatologie-Nutrition-Endocrinologie-Diabetologie (M.I.R.N.E.D.) (head Pr E Andres), Centre spécialisé de l’obésité (CSO) (Pr A Pradignac, Dr M Vix); Service d’Hépato-Gastroentérologie et d’Assistance Nutritive, (Pr JM Reimund), Chirurgie Générale et Digestive (head Pr S Rohr)

CHU de Reims

Pôle de Biologie Médicale et Pathologie. Service de Biochimie-Pharmacologie-Toxicologie (Pr Philippe Gillery); Centre spécialisé de l’obésité (CSO) (Pr E Bertin)

Non-institutional partners

Plant Advanced Technologies (PAT) is a France-based life sciences company established in Nancy, focusing on eco-friendly plant extracts production for pharmaceutical and cosmetic industries. It is engaged in the research and development in the field of plant biotechnology. The Company patented PAT Plant Milking®, a compounds production system based on roots exudation of plants grown hydroponically or PAT Friday, a recombinant protein expression system. In addition, PAT is involved in the development and sale of know-how, licenses and sub-licenses for its technologies. Jean-Paul Fèvre is Chief Executive Officer and Frederic Bourgaud, Chief scientific officer.

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (peptide LR12), with applications in a number of therapeutic indications. Dr Jean-Jacques Garaud is CEO of Inotrem and Professor Sébastien GIBOT is co-founder of Inotrem and chair of the scientific board of the company.

Promoting the involvement of researchers

into translational and clinical research

Members of the consortium have worked together in the recent past, enabling the FHU project to be assembled in the full confidence that all partners can rely on their synergies and complementary roles in the project. In particular, the multi-domain analysis capabilities of databases will enable us to view each partner specialisation as a facet of a single broader concept. Having worked together successfully in the past, the consortium has a clear idea of what they want to achieve and how to go about doing so. The project is closely aligned with the research strategies of the partners  – as is explored in WP3 and the potential for future joint action is already clear. Rather than a standalone research initiative, the FHU is a consortium that will irrigate the improvement of patient management and treatment through the production of validated biomarkers and better use of therapies, including bariatric surgery.

The consortium brings together leading research teams and SMEs in the complementary fields of nutrition, ageing, bio-informatics, biomarker analyses and drug repurposing. The project will develop cutting-edge bio-informatic and statistical technology for the analysis of a spectrum of different types, formats and granularities of data.

Consortium investment will complement contribution in terms of:

• Access to cohorts and infrastructure – partners will provide access to cohorts and bio-bank samples, which have been collected over many years.
• Use technologies and expertise of Medalis and SMEs for innovative treatments with repurposed molecules.
• Time and contributions by senior members of research groups

The consortium will be stimulated by the exchange of knowledge across the network during the project. Opportunities for further collaboration in national and international calls will also be explored through a joint research action plan. Each partner has existing networks of international collaborations that will benefit to the other partners.

Governance

The main components of the management structure of ARRIMAGE are: The Coordinator and Deputy Coordinators, the Executive Committee (or ExC), the Project Management Team and the Scientific Advisory Board. The ARRIMAGE Coordinator, Jean-Louis Guéant, will take overall responsibility for coordinating the overall progress of the project and will be assisted by two Deputy Coordinators, Pr E Andres, for Strasbourg site and Pr Gillery for Reims site. An administrative assistant and a secretary will help the coordinator and deputy coordinators in the day-to-day project management, administration and logistic The Coordinator and deputy coordinators will chair the Executive Committee (ExC) and ensure smooth operation of the project, progress reports and deliverables and budget handling. Particular emphasis will be placed on international attractiveness, by promoting the recruitment of young talents and / or young teams recognized and with very high potential (eg ERC, ATIP avenir). The ExC is composed of the coordinator, the deputy coordinators, the work package and task force leaders. The ExC is in charge of the operational management of all the activities of ARRIMAGE. Meetings of the ExC will be held every 3 months. Each WP leader will coordinate a WP committee composed of task coordinators. Meetings of all FHU staff are held once a year, with presentations of data and a special attention dedicated to PhD students and post docs. A discussion on the management of the FHU will be included in the program of each meeting. The Scientific Advisory Board is a consultative body composed of independent international scientists, chaired by one of them. We have proposed to the following leading scientists to participate in SAB: Pr D Alpers, Washington University, (I-CM /gastroenterology); Pr C Day, University Hospital Newcastle (pathological obesity and NASH), Pr Y Boirie, Université d’Auvergne (pathological obesity).